ArticleBritish journal of clinical pharmacology2004
Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study.
Article in British journal of clinical pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Oral anticoagulant timing and hospitalization in newly diagnosed nonvalvular atrial fibrillation patients.Frontiers in cardiovascular medicine · 2025Article
- The Prevalence and Determinants of Inappropriate Oral Anticoagulant Use in Patients with Atrial Fibrillation, in Resource-Limited Setting.BioMed research international · 2023Article
- Barriers and facilitators to optimal oral anticoagulant management: a scoping review.Journal of thrombosis and thrombolysis · 2020Article
- Geriatric Elements and Oral Anticoagulant Prescribing in Older Atrial Fibrillation Patients: SAGE-AF.Journal of the American Geriatrics Society · 2020Article
- Safety and feasibility of interventional left atrial appendage closure without contrast agent.AsiaIntervention · 2018Article
- The Utilization of Antithrombotic Therapy in Older Patients in Aged Care Facilities With Atrial Fibrillation.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018Article
- Atrial Fibrillation in Hypertension: Patients' Characteristics.Materia socio-medica · 2018Article
- All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2017Article
- Structured care of patients with atrial fibrillation improves guideline adherence.Journal of atrial fibrillation · 2016Article
- Efficacy and safety of novel anticoagulants in the elderly.Journal of geriatric cardiology : JGC · 2016Review
- Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany - results from the German AFNET registry.BMC neurology · 2015Observational
- Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use.Journal of thrombosis and thrombolysis · 2015Observational
- Risk scores and geriatric profile: can they really help us in anticoagulation decision making among older patients suffering from atrial fibrillation?Clinical interventions in aging · 2014Article
- Guideline adherence of antithrombotic treatment initiated by general practitioners in patients with nonvalvular atrial fibrillation: a Danish survey.Clinical cardiology · 2013Article
- Advances in stroke prevention in atrial fibrillation: enhanced risk stratification combined with the newer oral anticoagulants.Clinical cardiology · 2013Review
- Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient.International journal of general medicine · 2013Article
- Diagnosis and management of atrial fibrillation by primary care physicians in Italy : a retrospective, observational analysis.Clinical drug investigation · 2012Article
- Underprescription of beneficial medicines in older people: causes, consequences and prevention.Drugs & aging · 2012Review
- Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions.Thrombosis · 2012Article
- [Management and therapy of atrial fibrillation in geriatric patients].Zeitschrift fur Gerontologie und Geriatrie · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim of the Stroke and Atrial Fibrillation Ensemble (SAFE) II study was to identify the reasons underlying the under-utilization of oral anticoagulation (OAC) in patients with nonvalvular atrial fibrillation (NVAF).
methodsWe investigated from all available sources the reasons why patients hospitalized for a stroke, who had a previously known NVAF, were not receiving OAC beforehand. We interviewed general practitioners (GPs) and cardiologists with a structured questionnaire, to identify the reasons for their therapeutic choice.
resultsOf 370 patients, 257 were theoretically eligible for OAC according to guidelines and the presence of contra-indications, but only 82 (22.2%) of them had actually received OAC before. We found that factors independently associated with the prescription of OAC were being followed-up by a cardiologist and having a younger GP. The leading reason evoked by GPs or cardiologists to explain why patients were not treated with OAC was the presence of a 'potential contra-indication', which was often inappropriate, followed by 'there was no indication', 'low compliance' and 'fear of bleeding'.
conclusionsAn important reason for not prescribing OAC was the lack of knowledge about trials and guidelines. Medical education about OAC in NVAF should therefore be improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.